

COVID-19: KEEPING UP WITH A MOVING TARGET Oct 14, 2020 UPDATE



Paul Auwaerter, MD, MBA, FIDSA Clinical Director, Division of Infectious Diseases Sherrilyn and Ken Fisher Professor of Medicine Fisher Center for Environmental Infectious Diseases Johns Hopkins University School of Medicine











CME Information

Jointly provided by Postgraduate Institute for Medicine, DKBmed, and the Institute for Johns Hopkins Nursing.

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:

Name of Faculty or Presenter	Reported Financial Relationship
Paul G. Auwaerter, MD, MBA, FIDSA	Scientific Advisor: DiaSorin, Shionogi Inc. JNJ: Ownership equity

Dr. Auwaerter has indicated that he will be referencing the unlabeled or unapproved use of agents currently being investigated in on-going studies and trials, including a monoclonal antibody cocktail, dexamethasone, and several vaccine platforms.

All activity, content, and materials have been developed solely by the activity directors, planning committee members, and faculty presenters, and are free of influence from a commercial entity.







CME Information

To attest for CME/CE/AAPA credit, please visit

COVID19.dkbmed.com







Learning Objectives

- Discuss current status of vaccine development
- Discuss indication for dexamethasone in treatment of COVID-19







Thank You

This activity is supported by an educational grant from Pfizer, Inc. and in-kind support by DKBmed, LLC.

All activity content and materials have been developed solely by the activity directors, planning committee members, and faculty presenters.

Please see **COVID19.DKBmed.com** for additional resources and educational activities





Paul Auwaerter, MD, MBA, FIDSA

Clinical Director, Division of Infectious Diseases Sherrilyn and Ken Fisher Professor of Medicine Fisher Center for Environmental Infectious Diseases Johns Hopkins University School of Medicine









To submit your own question, please email QA@dkbmed.com









Any news on the possibility of a one dose vs. two dose vaccine?









Are the rapid antigen tests relatively inaccurate? What role should they play in screening?









Often, a COVID-19 patient can demonstrate improvement before experiencing a worsening of symptoms. Do we have a general timeline for when an improving patient could be considered "out of the woods"?









I am a school nurse and have concerns about students with simple common cold symptoms being asked to stay home until the symptoms resolve.

When I think about how many students in an elementary school have a runny nose or mild cough or occasional sneeze, I feel like half the students will be asked to stay home and we may as well just stay virtual. Any advice or comment to this thought?









What is the real information about the Regeneron cocktail?

Is it really that close in trials to production and general use?

Was the President just feeling better because of the steroids he was on?

Is this available for compassionate use?









What do we know about the cases of prolonged illness from COVID that are described as "long haulers"?









What are the indications for dexamethasone use in COVID-19 patients?

Are there any extenuating circumstances to these indications?







Is there evidence that eyeglasses are protective against infection?







To receive CME/CE/AAPA credit:

- Complete the evaluation on at COVID19.DKBmed.com
- Upon registering and successfully completing the activity evaluation, you will have immediate access to your certificate.

To access more resources related to COVID-19:

Access our resource hub at COVID19.DKBmed.com

To ask your own question, email: QA@dkbmed.com



